ArticleRegenerative biomaterials2025
Fibroblast-loaded carboxymethyl chitosan-aldehyde hyaluronic acid injectable hydrogel for scleral remodelling to prevent development of myopia.
Article in Regenerative biomaterials, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
2 citing papers in PubMed.
- Study on 3D-printed methacrylated hyaluronic acid/methacrylated carboxymethyl chitosan/curcumin composite scaffolds for jaw bone regeneration.BMC oral health · 2026Article
- [Research progress and applications of biologically derived materials in scleral reconstruction].Zhongguo xiu fu chong jian wai ke za zhi = Zhongguo xiufu chongjian waike zazhi = Chinese journal of reparative and reconstructive surgery · 2026Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
10 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
High myopia severely threatens the visual health of adolescents, with pathological features of decreased collagen aggregation and scleral thinning, ultimately leading to axial elongation on preretinal imaging. Fibroblasts play crucial roles in scleral remodelling and myopia prevention. In this work, we developed a fibroblast-loaded carboxymethyl chitosan-aldehyde hyaluronic acid (CMCS-HA-CHO) injectable hydrogel for anti-scleral remodelling. The CMCS-HA-CHO hydrogel is formed through simple mixing under mild conditions via a Schiff base reaction between CMCS and HA-CHO. The CMCS-HA-CHO hydrogel can be injected into a posterior sclera with a low modulus, and the increasing modulus over time provides good mechanical support to the sclera. The hydrogel demonstrated excellent cytocompatibility and haemocompatibility, and the encapsulated fibroblasts maintained good activity. Both the hydrogel and fibroblast-loaded hydrogel effectively shortened the axial length of myopic eyes in guinea pigs in a deprivation model. In particular, the fibroblast-loaded hydrogel had the best therapeutic effect because of the synergy of cell therapy and mechanical support, which always shortened the eye axis within 4 weeks. Furthermore, increased collagen secretion promoted by fibroblasts can increase the thickness of the sclera and improve its biomechanical properties, ultimately repairing the physiological structure of the sclera. This fibroblast-loaded injectable hydrogel may represent a promising clinical approach for controlling myopia progression.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.